Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.
- HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.
- Under the terms of the agreement, Ono has obtained an option to in-license NM49 from Numab for global development and commercialization, with Numab retaining an option to co-develop and commercialize in the United States.
- “This important partnership marks our third collaboration with Ono and the first one where Numab has the option to co-develop and commercialize in the United States.
- We are thrilled to continue working with Ono on developing new high impact multi-specific therapeutics for cancer patients,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics.